JLPC(SH:600513) Ge Long Hui·2025-09-12 10:03Group 1 - The core point of the article is that Lianhuan Pharmaceutical announced a transaction involving the purchase of certain real estate and land use rights from its controlling shareholder for 74.5 million RMB (excluding tax) [1] - The transaction is classified as a related party transaction and does not constitute a major asset restructuring as defined by the regulations [1] - The transaction has been approved by the company's board of directors and supervisory board, but it still requires approval from the shareholders' meeting and must go through state-owned asset approval and transfer registration procedures [1] Group 2 - The purpose of the transaction is to optimize resource allocation, expand asset scale, and enhance overall strength [1]